GLAXOSMITHKLINE PLC ADR (NYSE: GSK)

NYSE: GSK (GSK plc)

Kemas kini terakhir: 5 jam lalu

-2.48 (-6.36%)

Tambah ke senarai pantauan

Harga / Pendapatan (P/E TTM)	22.41
Harga / Pendapatan (P/E Ke hadapan)	8.22
Harga / Jualan (P/S)	1.84
Harga / Buku (P/B)	4.15

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Drug Manufacturers - General (US)	Menaik	Menaik
	Drug Manufacturers - General (Global)	Menaik	Menaik
Stok	GSK plc	Bercampur	Menaik

AISkor Stockmoo

-0.5

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
GSK	78 B	3.15%	22.41	4.15
JNJ	358 B	3.34%	25.63	5.39
ABBV	331 B	3.36%	78.23	99.47
PFE	127 B	7.56%	15.85	1.48
BMY	113 B	4.38%	-	7.42
LLY	663 B	0.73%	62.88	52.04

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Sektor	Healthcare
Industri	Drug Manufacturers - General
Gaya Pelaburan	Large Value
% Dimiliki oleh Orang Dalam	0.06%
% Dimiliki oleh Institusi	17.05%

Pemilikan

Nama	Tarikh	Syer Dipegang
Dodge & Cox	31 Dec 2024	68,440,912
Primecap Management Co/Ca/	31 Dec 2024	25,261,660
Jtc Employer Solutions Trustee Ltd	31 Dec 2024	20,278,564
Mondrian Investment Partners Ltd	31 Dec 2024	5,838,384
Grantham, Mayo, Van Otterloo & Co. Llc	31 Dec 2024	4,153,616
Equity Investment Corp	31 Dec 2024	3,962,581

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
25 Mar 2025	Pengumuman	Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older
17 Feb 2025	Pengumuman	PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
04 Feb 2025	CNBC	Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
27 Jan 2025	CNBC	Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
17 Jan 2025	CNBC	Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
13 Jan 2025	Pengumuman	GSK Enters Agreement to Acquire IDRx, Inc.

Hasil Dividen (DY TTM)	3.15%
Purata Hasil Dividen 3T	3.09%
Nisbah Pembayaran	97.83%
Jangkaan Pembayaran Dividen Seterusnya	Jul 2025

Tarikh EX	Tarikh Pengumuman	Tarikh Pembayaran	Perincian
15 Nov 2024	30 Oct 2024	09 Jan 2025	0.389052 Tunai
16 Aug 2024	31 Jul 2024	10 Oct 2024	0.385671 Tunai
16 May 2024	01 May 2024	11 Jul 2024	0.376185 Tunai
22 Feb 2024	01 Feb 2024	11 Apr 2024	0.4060608 Tunai
16 Nov 2023	01 Nov 2023	11 Jan 2024	0.3397772 Tunai
17 Aug 2023	26 Jul 2023	12 Oct 2023	0.361256 Tunai
18 May 2023	26 Apr 2023	13 Jul 2023	0.347508 Tunai
23 Feb 2023	01 Feb 2023	13 Apr 2023	0.3403867 Tunai
17 Nov 2022	02 Nov 2022	12 Jan 2023	0.3171217 Tunai
18 Aug 2022	27 Jul 2022	06 Oct 2022	0.390832 Tunai

Hasil Dividen Tahunan

Tahun	Dividen Tahunan ($)	Kekerapan/Tahun	Hasil %
2025	0.389	1	1.07
2024	1.51	4	4.46
2023	1.37	4	3.69
2022	0.391	1	1.11

Portfolio

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Tiada saham yang memenuhi kriteria anda

Margin Keuntungan	8.21%
Margin Operasi (TTM)	12.28%
EPS Cair (TTM)	1.63
Pertumbuhan Hasil Suku Tahunan (YOY)	0.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY)	18.30%

Jumlah Hutang/Ekuiti (D/E MRQ)	129.80%
Nisbah Semasa (MRQ)	0.780
Aliran Tunai Operasi (OCF TTM)	6.55 B
Aliran Tunai Bebas Leveraj (LFCF TTM)	4.90 B

Pulangan Atas Aset (ROA TTM)	6.53%
Pulangan Atas Ekuiti (ROE TTM)	22.80%